Sugiu, Kazuhisa
Tazawa, Hiroshi http://orcid.org/0000-0003-4658-1050
Hasei, Joe http://orcid.org/0000-0002-4028-0786
Yamakawa, Yasuaki http://orcid.org/0000-0002-4210-759X
Omori, Toshinori
Komatsubara, Tadashi
Mochizuki, Yusuke http://orcid.org/0000-0002-3415-2796
Kondo, Hiroya http://orcid.org/0000-0002-4642-5448
Osaki, Shuhei http://orcid.org/0000-0002-0498-5017
Fujiwara, Tomohiro http://orcid.org/0000-0003-4257-9180
Yoshida, Aki http://orcid.org/0000-0002-4790-933X
Kunisada, Toshiyuki http://orcid.org/0000-0002-1775-850X
Ueda, Koji http://orcid.org/0000-0001-9066-4959
Urata, Yasuo
Kagawa, Shunsuke http://orcid.org/0000-0002-3610-8211
Ozaki, Toshifumi
Fujiwara, Toshiyoshi http://orcid.org/0000-0002-5377-6051
Funding for this research was provided by:
The Japan Agency for Medical Research and Development (17ck0106285h001)
The Ministry of Education, Culture, Sports, Science, and Technology, Japan (25293238, 16H05416, 25293323, 25462333, 16K10862, 15K10446, 16K10596)
Article History
Received: 17 December 2020
Accepted: 31 May 2021
First Online: 10 June 2021
Declarations
:
: Y. Urata is President and CEO of Oncolys BioPharma, Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma, Inc. The other authors have no potential conflicts of interest to disclose.